Medtech companies have typically seen a “mixed picture of growth” in China in the past year or two, but it is a market that requires ongoing commitment, a panel of experts argued at the MedTech Forum 2024.

The US FDA approved Lilly’s Kisunla (donanemab) for early Alzheimer’s disease and the anti-amyloid antibody will launch into a challenging market primed by Eisai/Biogen’s Leqembi.

Sanofi’s voluntary Dengvaxia withdrawal due to low demand leaves the US with no dengue vaccine, even as Puerto Rico declares a public health emergency and global cases rise.

However, the US FDA’s approval of donanemab comes with little guidance on when to stop treatment or when the anti-amyloid agent may need to be restarted in Alzheimer’s patients.